Levofloxacin (Levaquin): Clinical Overview
Levofloxacin is a respiratory fluoroquinolone indicated for adults ≥18 years with a broad range of bacterial infections, with FDA-approved dosing ranging from 250-750 mg once daily depending on the infection type and severity. 1
FDA-Approved Indications
Levofloxacin is approved for the following infections in adults:
Respiratory Tract Infections
Community-Acquired Pneumonia (CAP):
- Standard regimen: 500 mg once daily for 7-14 days 1
- High-dose short-course: 750 mg once daily for 5 days 1
- Covers S. pneumoniae (including multidrug-resistant strains), H. influenzae, M. catarrhalis, atypical pathogens (Mycoplasma, Chlamydophila, Legionella) 1
- Not first-line for previously healthy adults; reserved for patients with comorbidities or recent antibiotic exposure (within 3 months) 2
Nosocomial Pneumonia: 750 mg once daily for 7-14 days; requires combination therapy with antipseudomonal β-lactam when Pseudomonas aeruginosa is suspected 1
Acute Bacterial Sinusitis: 500 mg once daily for 10-14 days OR 750 mg once daily for 5 days 1
Acute Bacterial Exacerbation of Chronic Bronchitis: 500 mg once daily for 7 days 1
Urinary Tract Infections
Complicated UTI:
Acute Pyelonephritis: 250 mg once daily for 10 days OR 750 mg once daily for 5 days 1
Uncomplicated UTI: 250 mg once daily for 3 days 1
Skin and Soft Tissue Infections
- Complicated: 750 mg once daily for 7-14 days (MSSA, Enterococcus, Streptococcus, Proteus) 1
- Uncomplicated: 500 mg once daily for 7-10 days (MSSA, S. pyogenes) 1
Other Indications
- Chronic Bacterial Prostatitis: 500 mg once daily for 28 days 1
- Inhalational Anthrax (post-exposure): Dosing per FDA guidance; safety beyond 28 days in adults not established 1
- Plague (treatment and prophylaxis): Approved for adults and pediatric patients ≥6 months 1
Key Dosing Principles
The 750 mg high-dose, 5-day regimen was specifically designed to overcome fluoroquinolone resistance mechanisms through maximized drug exposure 2. This regimen is FDA-approved for CAP, acute bacterial sinusitis, complicated UTI, and acute pyelonephritis 3.
Critical Contraindications and Black Box Warnings
While the provided evidence doesn't detail specific contraindications, fluoroquinolones as a class carry serious warnings including:
- Tendonitis and tendon rupture (5 cases of mostly reversible tendonitis reported in clinical trials) 4
- CNS effects including seizures
- Peripheral neuropathy
- QTc prolongation
- Glucose disturbances
- Photosensitivity (though levofloxacin has lower photosensitizing potential than some other quinolones) 5
Resistance Considerations
Critical caveat: Levofloxacin resistance in S. pneumoniae remains <1% overall in the US 5, but treatment failures have been documented with the 500 mg daily dose due to emerging resistance 2. Pseudomonas aeruginosa can develop resistance rapidly during therapy; periodic culture and susceptibility testing is essential 1.
Ciprofloxacin is NOT appropriate for community-acquired pneumonia due to inadequate pneumococcal coverage and resistance 2.
Counseling Points
- Bioequivalence: Oral formulation is bioequivalent to IV; seamless transition between routes is possible 3
- Once-daily dosing improves compliance 3
- Culture and susceptibility testing should be performed before treatment when possible 1
- Most common adverse events: nausea and diarrhea 5
- Avoid in areas with high Campylobacter resistance for traveler's diarrhea (resistance rates 57-88% in Taiwan, Thailand, Sweden) 2
Clinical Algorithm for Use
- First-line consideration: Reserve for patients with comorbidities, recent antibiotic exposure, or documented resistance to first-line agents
- Dose selection: Use 750 mg regimen for severe infections or when resistance is a concern
- Duration: Favor shorter courses (5 days with 750 mg) when appropriate to minimize resistance development
- Monitoring: Obtain cultures before initiating therapy; repeat if clinical failure occurs
- Combination therapy: Required for nosocomial pneumonia with suspected Pseudomonas 1